<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00093457</url>
  </required_header>
  <id_info>
    <org_study_id>I167</org_study_id>
    <secondary_id>CAN-NCIC-IND167</secondary_id>
    <secondary_id>CDR0000387987</secondary_id>
    <nct_id>NCT00093457</nct_id>
  </id_info>
  <brief_title>Sorafenib in Treating Patients With Metastatic or Recurrent Prostate Cancer</brief_title>
  <official_title>A Phase II Study Of BAY 43-9006 (NSC 724772; CTEP IND# 69,896) In Patients With Hormone Refractory Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NCIC Clinical Trials Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Canadian Cancer Trials Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Sorafenib may stop the growth of tumor cells by blocking the enzymes necessary for&#xD;
      their growth.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying the effectiveness of sorafenib in treating patients&#xD;
      who have metastatic or recurrent prostate cancer that has not responded to previous hormone&#xD;
      therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the efficacy of sorafenib, as measured by prostate-specific antigen response,&#xD;
           in patients with metastatic or recurrent hormone-refractory adenocarcinoma of the&#xD;
           prostate.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the objective response rate and duration of response in patients treated with&#xD;
           this drug.&#xD;
&#xD;
        -  Determine the tolerability and toxicity of this drug in these patients.&#xD;
&#xD;
        -  Determine time to treatment failure and overall survival in patients treated with this&#xD;
           drug.&#xD;
&#xD;
        -  Explore the relationship between measures of ras/raf pathway activation (pERK) and&#xD;
           response to treatment in these patients.&#xD;
&#xD;
      OUTLINE: This is a non-randomized, multicenter study.&#xD;
&#xD;
      Patients receive oral sorafenib twice daily on days 1-28. Courses repeat every 28 days in the&#xD;
      absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Patients are followed at 4 weeks after going off study treatment and then periodically for&#xD;
      survival. Patients with stable or responding disease, when they go off study treatment, are&#xD;
      followed every 3 months until relapse or progression.&#xD;
&#xD;
      PROJECTED ACCRUAL: Approximately 15-25 patients will be accrued for this study within 12-18&#xD;
      months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 21, 2004</start_date>
  <completion_date type="Actual">January 18, 2011</completion_date>
  <primary_completion_date type="Actual">September 28, 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Prostate-specific antigen response and/or progression</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response and/or progression</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability and toxicity</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to treatment failure and overall patient survival</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">28</enrollment>
  <condition>Prostate Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sorafenib tosylate</intervention_name>
    <description>BAY 43-9006 given orally at 400 mg BID in a 28 day cycle</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed adenocarcinoma of the prostate&#xD;
&#xD;
               -  Metastatic or recurrent disease&#xD;
&#xD;
          -  No curative standard therapy exists&#xD;
&#xD;
          -  Hormone-refractory disease&#xD;
&#xD;
               -  Evidence of prostate-specific antigen (PSA) progression during androgen ablation&#xD;
                  therapy, including medical or surgical castration&#xD;
&#xD;
                    -  Documented PSA progression after completion of prior peripheral&#xD;
                       anti-androgens&#xD;
&#xD;
                         -  At least a 25% increase (≥ 5 ng/mL) over a reference value PSA with 2&#xD;
                            consecutive rising PSAs taken ≥ 1 week apart&#xD;
&#xD;
                    -  Castrate level of testosterone ≤ 1.7 nmol/L for patients on medical androgen&#xD;
                       ablation&#xD;
&#xD;
                         -  Patients receiving luteinizing hormone-releasing hormone agonist&#xD;
                            therapy must continue this treatment during study participation&#xD;
&#xD;
          -  PSA ≥ 10 ng/mL at the time of study entry&#xD;
&#xD;
          -  Primary tumor tissue (paraffin embedded) must be available for immunohistochemistry&#xD;
&#xD;
          -  Minimal symptomatic disease&#xD;
&#xD;
               -  No requirement for morphine or equivalent dose &gt; 30 mg/day to control pain&#xD;
&#xD;
          -  No known brain metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-1&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  At least 12 weeks&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute granulocyte count ≥ 1,500/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
          -  No evidence of bleeding diathesis&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin normal&#xD;
&#xD;
          -  AST and ALT ≤ 2.5 times upper limit of normal&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Serum creatinine normal OR&#xD;
&#xD;
          -  Creatinine clearance ≥ 60 mL/min&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No myocardial infarction within the past 6 months&#xD;
&#xD;
          -  No congestive heart failure&#xD;
&#xD;
          -  No unstable angina&#xD;
&#xD;
          -  No active cardiomyopathy&#xD;
&#xD;
          -  No unstable ventricular arrhythmia&#xD;
&#xD;
          -  No uncontrolled hypertension&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No serious infection&#xD;
&#xD;
          -  No active peptic ulcer disease&#xD;
&#xD;
          -  No upper gastrointestinal or other condition that would preclude study compliance with&#xD;
             oral medication&#xD;
&#xD;
          -  No uncontrolled psychotic disorder&#xD;
&#xD;
          -  No history of allergic reaction attributed to compounds of similar chemical or&#xD;
             biologic composition to sorafenib or other study agents&#xD;
&#xD;
          -  No other serious illness or medical condition that would preclude study participation&#xD;
&#xD;
          -  No other malignancy within the past 5 years except adequately treated non-melanoma&#xD;
             skin cancer or other curatively treated solid tumor&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Concurrent prophylactic filgrastim (G-CSF), sargramostim (GM-CSF), or other growth&#xD;
             factors allowed for the management of adverse events only&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  No prior chemotherapy&#xD;
&#xD;
          -  No other prior cytotoxic chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Concurrent steroids allowed provided there has been no increase in steroid&#xD;
             requirements within the past 4 weeks AND no increase in dose is planned&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  At least 4 weeks since prior external-beam radiotherapy except low-dose&#xD;
             non-myelosuppressive radiotherapy&#xD;
&#xD;
          -  Concurrent low-dose non-myelosuppressive palliative radiotherapy allowed&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No prior investigational anticancer agents&#xD;
&#xD;
          -  No concurrent therapeutic anticoagulation&#xD;
&#xD;
               -  Concurrent prophylactic low-dose warfarin for venous or arterial access devices&#xD;
                  allowed&#xD;
&#xD;
          -  No concurrent combination antiretroviral therapy for HIV-positive patients&#xD;
&#xD;
          -  No other concurrent anticancer therapy&#xD;
&#xD;
          -  No other concurrent investigational therapy&#xD;
&#xD;
          -  No concurrent grapefruit juice&#xD;
&#xD;
          -  Concurrent bisphosphonates allowed&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kim N. Chi, MD</last_name>
    <role>Study Chair</role>
    <affiliation>British Columbia Cancer Agency</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tom Baker Cancer Centre - Calgary</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>British Columbia Cancer Agency - Centre for the Southern Interior</name>
      <address>
        <city>Kelowna</city>
        <state>British Columbia</state>
        <zip>V1Y 5L3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>British Columbia Cancer Agency - Vancouver Cancer Centre</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CancerCare Manitoba</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3E 0V9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Margaret and Charles Juravinski Cancer Centre</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V 5C2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>London Regional Cancer Program at London Health Sciences Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <results_reference>
    <citation>Chi KN, Ellard SL, Hotte SJ, Czaykowski P, Moore M, Ruether JD, Schell AJ, Taylor S, Hansen C, Gauthier I, Walsh W, Seymour L. A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer. Ann Oncol. 2008 Apr;19(4):746-51. Epub 2007 Dec 3.</citation>
    <PMID>18056648</PMID>
  </results_reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>October 6, 2004</study_first_submitted>
  <study_first_submitted_qc>October 7, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 8, 2004</study_first_posted>
  <last_update_submitted>April 7, 2020</last_update_submitted>
  <last_update_submitted_qc>April 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent prostate cancer</keyword>
  <keyword>stage IV prostate cancer</keyword>
  <keyword>adenocarcinoma of the prostate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sorafenib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

